<DOC>
	<DOCNO>NCT02991638</DOCNO>
	<brief_summary>Efficacy Safety ibrutinib patient chronic lymphocytic leukemia indolent B-cell lymphoma chronic hepatitis B virus carrier occult hepatitis B virus carrier</brief_summary>
	<brief_title>Efficacy Safety Ibrutinib Patients With CLL Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers Occult Hepatitis B Virus Carriers</brief_title>
	<detailed_description>Ibrutinib selective oral Burton tyrosine kinase inhibitor . Through interfere downstream pathway B-cell receptor signaling , inhibit proliferation induces apoptosis many B-cell lymphoid malignancy . The clinical benefit ibrutinib demonstrate patient relapsed/refractory chronic lymphocytic leukaemia , mantle cell lymphoma , small lymphocytic lymphoma , indolent B-cell non-Hodgkin lymphoma . The pivotal trial ibrutinib exclude HBsAg+ patient . Therefore , effect ibrutinib HBsAg+ anti-HBc+ patient remain entirely undefined . In view B-cell signal inhibitory activity ibrutinib , might potent rituximab suppress B-cells , HBV reactivation patient expose previously HBV infection , include chronic HBV carrier occult HBV carrier , could major clinical problem . To enable ibrutinib prescribed Asia region world HBV endemic , evidence-based recommendation prevention HBV reactivation at-risk population , include chronic HBV carrier ( HBsAg+ ) , occult HBV carrier ( HBsAg- anti-HBc+ ) , urgently need . The following treatment regimen adopt . Relapsed / refractory chronic lymphocytic leukemia Waldenstrom macroglobulinaemia ( lymphoplasmacytic lymphoma ) : 420 mg daily . Relapsed / refractory mantle cell lymphoma : 560 mg daily . Relapsed / refractory indolent B-cell non-Hodgkin lymphoma : 560 mg daily . Treatment continue disease progression . A total 62 patient recruit , include 16 HBsAg+ patient , 46 occult HBV carrier Sample size calculation occult HBV carrier For occult HBV carrier , sample size calculate accord follow information , base previous observation ( detailed reference 3 ) . The HBV reactivation rate HBsAg- , anti-HBc+ , anti-HBs+ patient hypothesize 34 % , may increase 68 % HBsAg- , anti-HBc+ , anti-HBs- patient [ 3 ] . Assuming power 80 % alpha-risk 0.1 , together ratio anti-HBs+ : anti-HBs- patient 2:1 , expect recruit 42 HBsAg- , anti-HBc+ patient . With dropout rate 10 % , total number patient recruit group 46 . Sample size calculation HBsAg+ patient For HBsAg+ patient , sample size calculate accord follow information , base previous observation ( detailed reference 3 ) . The ratio occult carrier ( HBsAg- , anti-HBc+ ) : HBsAg+ patient 3 : 1.3 Hence , total number HBsAg+ recruit 14 ( 42 divide 3 ) . With drop-out rate 10 % , total number patient recruit group 16 . Approximate breakdown number patient category recruit Based previous observation proportion low-grade B-cell lymphoid malignancies,8 approximate breakdown number patient follow : follicular lymphoma ( N=32 ) , chronic lymphocytic leukemia/small lymphocytic lymphoma ( N=11 ) , marginal zone B-cell lymphoma ( N=11 ) , mantle cell lymphoma ( N=5 ) , Waldenstrom macroglobulinemia ( N=5 ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<criteria>1 . Adult patient age 18 80 year 2 . Patients indolent Bcell lymphoproliferative neoplasm relapse refractory least one standard line therapy contain rituximab 3 . Pathologically proven Bcell lymphoproliferative neoplasm include chronic lymphocytic leukaemia/small lymphocytic lymphoma , mantle cell lymphoma , marginalzone Bcell lymphoma , Waldenstrom macroglobulinaemia ( lymphoplasmacytic lymphoma ) . 4 . Pathologically proven follicular lymphoma , relapse disease progression &gt; 12 month previous rituximab therapy . 5 . Chronic HBV carrier ( HBsAg+ ) 6 . Occult HBV carrier ( HBsAg , antiHBc+ HBV DNA ) 7 . Haematology value within follow limit : 1 . Absolute neutrophil count ( ANC ) 1000/mm3 independent growth factor support 2 . Platelets 100,000/mm3 , 50,000/mm3 bone marrow involve , independent transfusion support either situation 8 . Biochemical value within follow limit : 1 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2 x upper limit normal ( ULN ) 2 . Total bilirubin ≤ 1.5 x ULN unless bilirubin rise due Gilbert 's syndrome nonhepatic origin 3 . Serum creatinine ≤ 2 x ULN estimate Glomerular Filtration Rate ( Cockcroft Gault ) ≥ 40 mL/min/1.73m2 9 . Competent give inform consent 1 . Concomitant chronic liver disease related HBV 2 . Known history druginduced liver injury , chronic active hepatitis C infection , alcoholic liver disease , nonalcoholic steatohepatitis , primary biliary cirrhosis , ongoing extrahepatic obstruction cause cholelithiasis , cirrhosis liver portal hypertension 3 . Known history drug induce pneumonitis 4 . Known history inflammatory bowel disease 5 . Woman pregnant breastfeed 6 . Patients consent use effective contraception study 7 . Active infection . 8 . Evidence ongoing active HBV hepatitis ( ALT and/or AST &gt; 2x upper limit normal , detectable HBV DNA ) 9 . Patients known histological transformation CLL aggressive lymphoma 10 . Vaccinated live , attenuated vaccine within 4 week enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>